Please login to the form below

Not currently logged in
Email:
Password:

Bristol-Myers Squibb names new CEO

Lamberto Andreotti will take over from James Cornelius as CEO at Bristol-Myers Squibb, with Cornelius staying on as chairman  

Bristol-Myers Squibb (BMS) has announced that Lamberto Andreotti, 59, will become the company's chief executive officer on May 4, when James M Cornelius, 66, current chairman and CEO, retires. At the request of the board, Cornelius will remain as chairman. 

"Jim successfully led our transformation into a next-generation biopharma leader with his strategic leadership and consistent focus on delivering our commitments. I am personally grateful for this opportunity to lead Bristol-Myers Squibb in the next phase of our biopharma journey," said Lamberto Andreotti, who is currently president, chief operating officer and a member of the board.  

Lamberto has the full support of Cornelius, who said: "Lamberto has demonstrated extraordinary leadership as president and chief operating officer and I believe he is the natural candidate to replace me as CEO. I have a high level of confidence in Lamberto and that is shared by everyone who has seen him consistently and successfully drive performance."  

Andreotti has been president and chief operating officer since March 2009, responsible for the global pharmaceutical business. He has been with BMS for 12 years in senior international roles. Prior to this he held senior roles at KABI Pharmacia and Pharmacia & Upjohn. 

3rd March 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics